🔬 MK-677 vs. MK-777 Research Overview

Comparing a Studied Ghrelin-Receptor Agonist With an Unverified Research Name

MK-677, also known as ibutamoren, is an investigational, orally active, non-peptide growth-hormone secretagogue. It has been evaluated in published human clinical studies examining growth hormone, IGF-1, body composition, glucose regulation, and other biological outcomes.

By contrast, MK-777 and the name “IbutanoMorelin” do not appear to have an established identity in peer-reviewed scientific literature. No recognized chemical structure, pharmacological characterization, registered clinical trials, or independently published studies could be verified under those names.

Therefore, MK-677 and MK-777 cannot currently be treated as two scientifically established analogues within the same drug class.

Neither compound is approved by the FDA for human use.

🧬 What Is MK-677?

MK-677 is a small-molecule agonist of the growth-hormone secretagogue receptor, also known as the ghrelin receptor or GHS-R1a.

Activation of this receptor can stimulate the pituitary release of growth hormone, which may subsequently increase circulating insulin-like growth factor 1.

Research involving MK-677 has examined:

• Pulsatile growth-hormone secretion

• Circulating IGF-1

• Fat-free mass

• Body water

• Glucose and insulin sensitivity

• Appetite signaling

• Sleep architecture

• Bone turnover

• Muscle strength and physical function

MK-677 is not a SARM, anabolic steroid, peptide, or form of synthetic growth hormone. It stimulates a receptor involved in endogenous growth-hormone signaling.

🔬 Published MK-677 Research

Growth Hormone and IGF-1

Controlled human studies have demonstrated that MK-677 can increase growth-hormone secretion and circulating IGF-1 under experimental conditions.

In a randomized study involving 65 adults between 60 and 81 years old, MK-677 increased average growth-hormone and IGF-1 concentrations over 12 months.

The study also found that the normal pulsatile pattern of growth-hormone secretion was maintained, with an increase in the amount released during individual pulses.

These hormonal findings demonstrate biological activity. They do not establish improved longevity, athletic performance, recovery, or quality of life.

Fat-Free Mass and Physical Function

In the same trial, average fat-free mass increased by approximately 1.1 kilograms in the MK-677 group while decreasing by approximately 0.5 kilograms in the placebo group.

However:

• The increase in fat-free mass did not produce significant improvements in strength.

• Physical function did not significantly improve.

• Total body weight increased.

• Some of the change involved intracellular and extracellular water.

• Abdominal visceral fat did not significantly decrease.

• Total fat mass did not significantly improve.

An increase in measured fat-free mass should not automatically be described as an equivalent increase in functional skeletal muscle.

Glucose Regulation

The clinical trial also reported:

• An average increase in fasting blood glucose

• Reduced insulin sensitivity

• Increased appetite

• Mild lower-extremity edema

• Muscle discomfort in some participants

These findings are particularly important because growth-hormone and IGF-1 signaling can interact with glucose metabolism.

Research demonstrating elevated GH and IGF-1 does not establish that chronic stimulation is metabolically harmless.

Sleep Research

Earlier experimental studies investigated the relationship between MK-677 and sleep architecture. Changes in certain stages of sleep were reported under controlled conditions.

However, these findings do not establish that MK-677 reliably improves insomnia, sleep quality, daytime energy, memory, or cognitive performance.

Sleep-stage measurements are biological outcomes and should not automatically be presented as meaningful clinical benefits.

Bone Research

MK-677 has also been examined for effects on bone-turnover markers and bone mineral density.

Some findings were consistent with increased bone remodeling, but this does not establish stronger bones or reduced fracture risk. Increased bone turnover can reflect simultaneous changes in both bone formation and breakdown.

Long-term clinical outcomes have not established MK-677 as a treatment for osteoporosis or skeletal injury.

🧪 What Is Known About MK-777?

Very little verifiable scientific information is available for MK-777.

The claims that MK-777 is:

• An analogue of MK-677

• Also known as “IbutanoMorelin”

• A ghrelin-receptor agonist

• Capable of increasing GH or IGF-1

• Less likely to increase appetite

• Less likely to cause water retention

• More selective than MK-677

• Orally active

• Suitable for longer-term research

could not be confirmed through peer-reviewed studies or recognized pharmacological databases.

A similar product name does not establish chemical similarity. Without an independently verified molecular structure and pharmacological profile, it is impossible to conclude that MK-777 has the same mechanism as MK-677.

Reports of “cleaner gains,” reduced bloating, improved sleep, or greater tolerability are anecdotes and marketing claims—not clinical data.

⚖️ Evidence-Based Comparison

Research category

MK-677 (Ibutamoren)

MK-777 (“IbutanoMorelin”)

Recognized chemical identity

Yes

Not independently verified

Peer-reviewed studies

Yes

None located

Human clinical research

Yes

None located

Confirmed GHS-R1a activity

Yes

Not established

Demonstrated GH increase

Yes, in controlled studies

Not established

Demonstrated IGF-1 increase

Yes, in controlled studies

Not established

Fat-free-mass findings

Increased in some studies

No published data

Strength improvement

Not demonstrated in the major older-adult trial

No published data

Fat-loss effect

Not established

Not established

Appetite effects

Increased appetite reported

Unknown

Water-retention findings

Edema and body-water changes reported

Unknown

Glucose effects

Higher fasting glucose and reduced insulin sensitivity reported

Unknown

Sleep findings

Limited experimental data

Unknown

Long-term safety

Not established

Unknown

FDA approval

No

No

⚠️ Claims the Evidence Does Not Support

Current evidence does not establish that MK-677:

• Accelerates fat loss

• Produces functional muscle growth

• Improves athletic recovery

• Rejuvenates skin or hair

• Repairs joints

• Improves cognition

• Extends lifespan

• Is free from endocrine or metabolic consequences

• Is safe for long-term use

Current evidence also does not establish that MK-777:

• Is chemically related to MK-677

• Activates the ghrelin receptor

• Increases growth hormone or IGF-1

• Produces less hunger or water retention

• Improves sleep or recovery

• Has a particular half-life

• Avoids hormonal or metabolic effects

• Has undergone legitimate preclinical or clinical testing

Neither compound should be described as “non-suppressive” without defining the specific biological system being measured. A lack of evidence for testosterone suppression does not mean a compound has no endocrine effects.

⚠️ Research Limitations

MK-677

• Clinical populations and study designs have varied.

• Hormonal changes have not consistently produced functional benefits.

• Increased fat-free mass may partly reflect increased body water.

• Glucose regulation and insulin sensitivity are important concerns.

• Long-term safety has not been established.

• It is not approved as an anti-aging or body-composition treatment.

MK-777

• No verified chemical identity was located.

• No peer-reviewed pharmacology was located.

• No animal or human trials were located.

• No independently validated safety data were located.

• Mechanism, potency, selectivity, half-life, and interactions are unknown.

• Product labeling alone cannot establish compound identity.

⭐ Evidence-Based Verdict

MK-677 is a legitimate investigational compound with published evidence showing that it can increase growth hormone and IGF-1. In one major older-adult trial, it also increased fat-free mass, but did not improve strength or physical function and was associated with increased appetite, edema, higher fasting glucose, and reduced insulin sensitivity.

MK-777 is not scientifically comparable based on currently verifiable evidence. The name “IbutanoMorelin,” its claimed relationship to MK-677, and its proposed advantages could not be confirmed in peer-reviewed literature.

The most accurate conclusion is that MK-677 has documented biological activity and meaningful research limitations, while MK-777 remains an inadequately identified compound whose pharmacology and safety cannot presently be verified.

Learn more about MK-677 and MK-777

Affiliate disclosure: The link above is a referral link. I may receive a commission if it is used, at no additional cost to the purchaser.

For laboratory-research purposes only. Not for human or veterinary use.

This material is provided solely for general educational discussion of research. It is not medical advice, does not provide dosing or administration instructions, does not recommend personal use or self-experimentation, and does not claim that either compound can diagnose, treat, cure, or prevent any disease.